Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis

Ayodeji Adegunsoye; Julie Morisset; Chad A. Newton; Justin M. Oldham; Eric Vittinghoff; Angela L. Linderholm; Mary E. Strek; Imre Noth; Christine Kim Garcia; Paul J. Wolters; Brett Ley

doi:10.1183/13993003.02872-2020

Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis

Ayodeji Adegunsoye, Julie Morisset, Chad A. Newton, Justin M. Oldham, Eric Vittinghoff, Angela L. Linderholm, Mary E. Strek, Imre Noth, Christine Kim Garcia, Paul J. Wolters, Brett Ley

Research output: Contribution to journal › Letter › peer-review

36 Scopus citations

Original language	English (US)
Article number	2002872
Journal	European Respiratory Journal
Volume	57
Issue number	3
DOIs	https://doi.org/10.1183/13993003.02872-2020
State	Published - Mar 1 2021

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1183/13993003.02872-2020

Cite this

@article{fac82e2a029d4e858a464bd21bdbdc5f,

title = "Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis",

author = "Ayodeji Adegunsoye and Julie Morisset and Newton, {Chad A.} and Oldham, {Justin M.} and Eric Vittinghoff and Linderholm, {Angela L.} and Strek, {Mary E.} and Imre Noth and Garcia, {Christine Kim} and Wolters, {Paul J.} and Brett Ley",

note = "Funding Information: Conflict of interest: A. Adegunsoye reports personal fees from Genentech and Boehringer Ingelheim, outside the submitted work. J. Morisset has nothing to disclose. C.A. Newton has nothing to disclose. J.M. Oldham reports personal fees from Boehringer Ingelheim and Genentech, outside the submitted work. E. Vittinghoff has nothing to disclose. A.L. Linderholm has nothing to disclose. M.E. Strek reports grants from Boehringer Ingelheim, Galapagos and Novartis, outside the submitted work. I. Noth reports grants and personal fees from Boehringer Ingelheim (advisory boards), and personal fees from Intermune (advisory boards), Anthera (advisory boards), GSK (speaking honoraria) and Immuneworks (consulting fees), outside the submitted work. C.K. Garcia has nothing to disclose. P.J. Wolters reports grants and personal fees from Boehringer Ingelheim, personal fees from Blade therapeutics and Roche, and grants from Genentech, outside the submitted work. B. Ley reports grants from Nina Ireland Program for Lung Health, during the conduct of the study; personal fees from Genentech, outside the submitted work. Funding Information: NIH K23HL146942, NIH K23HL138190, NIH K23HL148498, NIH R01HL130796, NIH R01 HL093096, NIH KL2TR001870, and Nina Ireland Program for Lung Health. Funding information for this article has been deposited with the Crossref Funder Registry.",

year = "2021",

month = mar,

day = "1",

doi = "10.1183/13993003.02872-2020",

language = "English (US)",

volume = "57",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "3",

}

TY - JOUR

T1 - Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis

AU - Adegunsoye, Ayodeji

AU - Morisset, Julie

AU - Newton, Chad A.

AU - Oldham, Justin M.

AU - Vittinghoff, Eric

AU - Linderholm, Angela L.

AU - Strek, Mary E.

AU - Noth, Imre

AU - Garcia, Christine Kim

AU - Wolters, Paul J.

AU - Ley, Brett

N1 - Funding Information: Conflict of interest: A. Adegunsoye reports personal fees from Genentech and Boehringer Ingelheim, outside the submitted work. J. Morisset has nothing to disclose. C.A. Newton has nothing to disclose. J.M. Oldham reports personal fees from Boehringer Ingelheim and Genentech, outside the submitted work. E. Vittinghoff has nothing to disclose. A.L. Linderholm has nothing to disclose. M.E. Strek reports grants from Boehringer Ingelheim, Galapagos and Novartis, outside the submitted work. I. Noth reports grants and personal fees from Boehringer Ingelheim (advisory boards), and personal fees from Intermune (advisory boards), Anthera (advisory boards), GSK (speaking honoraria) and Immuneworks (consulting fees), outside the submitted work. C.K. Garcia has nothing to disclose. P.J. Wolters reports grants and personal fees from Boehringer Ingelheim, personal fees from Blade therapeutics and Roche, and grants from Genentech, outside the submitted work. B. Ley reports grants from Nina Ireland Program for Lung Health, during the conduct of the study; personal fees from Genentech, outside the submitted work. Funding Information: NIH K23HL146942, NIH K23HL138190, NIH K23HL148498, NIH R01HL130796, NIH R01 HL093096, NIH KL2TR001870, and Nina Ireland Program for Lung Health. Funding information for this article has been deposited with the Crossref Funder Registry.

PY - 2021/3/1

Y1 - 2021/3/1

UR - http://www.scopus.com/inward/record.url?scp=85102657843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85102657843&partnerID=8YFLogxK

U2 - 10.1183/13993003.02872-2020

DO - 10.1183/13993003.02872-2020

M3 - Letter

C2 - 33122338

AN - SCOPUS:85102657843

SN - 0903-1936

VL - 57

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 3

M1 - 2002872

ER -

Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this